Tilray Shares Slide Following Trio of Announcements Spanning Finance, Medical Cannabis, and Consumer Beverages
Tilray Brands Inc. (NASDAQ: TLRY) saw its stock retreat approximately 8% today after releasing a series of press announcements spanning multiple verticals—from corporate finance to new product launches in both the medical and recreational markets.
The most notable update came in the form of a proposed reverse stock split, where Tilray is seeking shareholder approval to consolidate its common stock at a ratio between 1-for-10 and 1-for-20. The move, announced ahead of a special meeting scheduled for June 10, 2025, is designed to help the company regain compliance with Nasdaq listing requirements. Executives also noted the split could lead to cost reductions exceeding $1 million annually and improve Tilray’s appeal to institutional investors.
Despite the financial restructuring effort, Tilray continues to build out its product pipeline and international reach. The company’s medical division launched its first-ever cannabis edibles in Australia under the Good Supply brand. The sugar-free, vegan-friendly pastilles come in several THC and CBD formulations and are available to patients via Tilray Direct and local distributors. The move marks an expansion of Tilray’s EU-GMP-certified portfolio, which now spans more than 20 countries.
On the consumer front, Tilray also announced the debut of a new ready-to-drink cocktail line under the name “Cruisies.” The beverages, which include flavors like Citrus Punch and Blueberry G&T, are being rolled out through the company’s existing U.S. distribution network, which includes wholesalers and on-premise accounts. The brand targets a younger, on-the-go consumer demographic and underscores Tilray’s ongoing push into the adult beverage market.
While each announcement represents a step forward in the company’s long-term strategy, the combination of a reverse stock split and mixed investor sentiment surrounding cannabis sector volatility has attributed to the negative pressure of the stock price.
